Amendments to the claims

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims

1. (cancelled)

2. (cancelled)

3. (withdrawn) A compound of claim 1, wherein R^1 is



4. (withdrawn) A compound of claim 1, wherein R^1 is



PAGE 3/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54

5. (withdrawn) A compound of claim 1, wherein R^1 is





6. (withdrawn) A compound of claim 1, wherein R^1 is



PAGE 4/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54

7. (withdrawn) A compound of claim 1, wherein R^1 is



or

8. (withdrawn) A compound of claim 1, wherein R^1 is



or

9. (currently amended) A compound of claim ~~1~~ 14, wherein s is one to two; R^3 is hydrogen or $(C_1$-$C_6)$alkyl; R^4 is ~~hydrogen,~~ $(C_1$-$C_6)$alkyl, perhalo$(C_1$-$C_6)$alkyl, phenyl, $(C_1$-$C_6)$alkyl-S-$(C_1$-

PAGE 5/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54

C_6)alkyl-, (C_5-C_{10})heteroaryl, (C_3-C_{10})cycloalkyl, aminoalkyl, amino(C=O)-, (C_1-C_6)alkyl-(C=O)-NH-(C_1-C_6)alkyl, or (C_1-C_6)alkyl-NH-(C=O)-(C_1-C_6)alkyl; and R^6 is H, (C_1-C_6)alkyl, (C_3-C_{10})cycloalkyl, (C_1-C_6)alkyl-(SO_2)-(C_1-C_6)alkyl, (C_1-C_6)alkyl-(SO_2)-NH-(C_1-C_6)alkyl, (C_1-C_6)alkyl-NH-(SO_2)-(C_1-C_6)alkyl, (C_1-C_6)alkyl-(C=O)-(C_1-C_6)alkyl, (C_3-C_{10})cycloalkyl-(C=O)-(C_3-C_{10})cycloalkyl, (C_1-C_6)alkyl-NH-(C=O)-(C_1-C_6)alkyl, (C_1-C_6)alkyl-(C=O)-NH-(C_1-C_6)alkyl, (C_3-C_{10})cycloalkyl-NH-(C=O)-(C_3-C_{10})cycloalkyl, or (C_3-C_{10})cycloalkyl-(C=O)-NH-(C_3-C_{10})cycloalkyl.

10. (original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

11. (withdrawn) A method of preventing or treating a TGF-related disease state in an animal or human comprising the step of administering a therapeutically effective amount of a compound of claim 1 to the animal or human suffering from the TGF-related disease state.

12. (withdrawn) A method of claim 11, wherein said TGF-related disease state is selected from the group consisting of cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.

13. (new) A compound selected from the group consisting of:

1 -Methyl-6-[5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-1H-benzotriazole;

6-[5-(6-Methyl-pyridin-2-yl)-1H-imidazol-4-yl]-1H-benzotriazole;

2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-2H-benzotriazole;

2-Methyl-5-[2-methyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-2H-benzotriazole;

6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-1H-benzotriazole;

1 -Methyl-6-[5-(6-methyl-pyridin-2-yl)-2-tifluoromethyl-1H-imidazol-4-yl]-1H-benzotriazole;

6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-1H-benzotriazole;

1 -Methyl-6-[2-methyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-1H-benzotriazole;

1 -Methyl-6-(2-methyl-5-pyridin-2-yl-1H-imidazol-4-yl)-1H-benzotriazole;

PAGE 6/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54

1-Methyl-6-[5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-1H-benzotriazole;

5-[2-(2-Benzo[1,3]dioxol-5-yl-1-methyl-ethyl)-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-2-methyl-2H-benzotriazole;

2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-2-(2-methylsulfanyl-ethyl)-1H-imidazol-4-yl]-2H-benzotiazole;

2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-2-thiazol-2-yl-1H-imidazol-4-yl]-2H-benzotriazole;

6-[2-Cyclopropyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-1-methyl-1H-benzotriazole;

5-[2-Cyclopropyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-2-methyl-2H-benzotriazole;

6-[2-Cyclopropyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline;

[4-(2-Methyl-2H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-methanol; and

4-(2-Methyl-2H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-1H-imidazole-2-carboxylic acid amide.

14. (new) A compound of formula (Ia):



(Ia)

PAGE 7/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54

or a pharmaceutically acceptable salt, prodrug, tautomer, hydrate, or solvate thereof, wherein:

R^1 is a benzotriazole selected from



, or

wherein said benzotriazole can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkoxy, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, oxo, mercapto, (C_1-C_6)alkylthio, (C_1-C_6)alkoxy, (C_5-C_{10})aryl, (C_5-C_{10})heteroaryl, (C_5-C_{10})aryloxy, (C_5-C_{10})heteroaryloxy, (C_5-C_{10})ar(C1-C6)alkyl, (C_5-C_{10})heterar(C_1-C_6)alkl, (C_5-C_{10})ar(C_1-C_6)alkoxy, (C_5-C_{10})heteroar(C_1-C_6)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C_1-C_6)alkyl, (C_1-C_6)alkylamino(C_1-C_6)alkyl, di(C_1-C_6)alkylamino(C_1-C_6)alkyl, (C_5-C_{10})heterocyclyl(C_1-C_6)alkyl, (C_1-C_6)alkyl- and di(C_1-C_6)alkylamino, cyano, nitro, carbamoyl, (C_1-C_6)alkylcarbonyl, (C_1-C_6)alkoxycarbonyl, (C_1-C_6)alkylaminocarbonyl, di(C_1-C_6)alkylaminocarbonyl, (C_5-C_{10})arylcarbonyl, (C_5-C_{10})aryloxycarbonyl, (C_1-C_6)alkylsulfonyl, and (C_5-C_{10})arylsulfonyl;

wherein R^{2a} is selected from the group consisting of carbonyl and carboxyl, or

R^{2a} is selected from the group consisting of (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, (C_3-C_{10})cycloalkyl, (C_5-C_{10})aryl, (C_1-C_6)alkylaryl, amino, (C_2-C_6)acid, (C_1-C_6)ester, (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclyl, (C_1-C_6)alkoxy, nitro, halo, hydroxyl, (C_1-C_6)alkoxy(C_1-C_6)ester; each of which may be optionally substituted by at least one moiety independently selected from the group consisting of halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_3-C_{10})cycloalkyl, (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclic, formyl, NC-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, ((C_1-C_6)alkyl)$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-

PAGE 8/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54

(C=O)-, O_2N-, amino, (C_1-C_6)alkylamino, ((C_1-C_6)alkyl)$_2$-amino, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, H_2N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-NH-, ((C_1-C_6)alkyl)$_2$N-(C=O)-NH-, (C_1-C_6)alkyl-HN-(C=O)-[((C_1-C_6)alkyl)-N]-, ((C_1-C_6)alkyl)$_2$N-(C=O)-[(C_1-C_6)alkyl-N]-, phenyl-HN-(C=O)-NH-, (phenyl)$_2$N-(C=O)-NH-, phenyl-HN-(C=O)-[((C_1-C_6)alkyl)-N]-, (phenyl-)$_2$N-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-O-(C=O)-NH-, (C_1-C_6)alkyl-O-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[(alkyl)-N]-, (C_1-C_6)alkyl-SO_2NH-, phenyl-SO_2NH-, (C_1-C_6)alkyl-SO_2-, phenyl-SO_2-, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_1-C_6)alkyl-(C=O)-O-, (C_1-C_6)ester-(C_1-C_6)alkyl-O-, phenyl-(C=O)-O-, H_2N-(C=O)-O-, (C_1-C_6)alkyl-HN-(C=O)-O-, ((C_1-C_6)alkyl)$_2$N-(C=O)-O-, phenyl-HN-(C=O)-O-, and (phenyl)$_2$N-(C=O)-O-;

each R^3 is independently selected from the group consisting of hydrogen and halo, or

R^3 is independently selected from the group consisting of halo(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_5-C_{10})heteroaryl-O-, (C_5-C_{10})heterocyclic-O-, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, O_2N-, NC-, amino, Ph(CH_2)$_{1-6}$HN-, (C_1-C_6)alkyl HN-, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[(((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, (C_5-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, [(C_1-C_6)alkyl]$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)- and (C_1-C_6)alkyl-(C=O)-O-; each of which may be optionally substituted by at least one substituent independently selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, halo(C_1-C_6)alkyl, halo, H_2N-, Ph(CH_2)$_{1-6}$HN-, and (C_1-C_6)alkylHN-;

s is an integer from one to five;

R^4 is independently selected from the group consisting of halo, or

R^4 is independently selected from the group consisting of halo(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, phenyl, (C_5-C_{10})heteroaryl, (C_5-

PAGE 9/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54

C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, phenoxy, (C_5-C_{10})heteroaryl-O-, (C_5-C_{10})heterocyclic-O-, (C_3-C_{10})cycloalkyl-O-, (C_1-C_6)alkyl-S-, (C_1-C_6)alkyl-S-(C_1-C_6)alkyl-, (C_1-C_6)alkyl-SO_2-, (C_1-C_6)alkyl-NH-SO_2-, O_2N-, NC-, amino, aminoalkyl, $Ph(CH_2)_{1-6}HN$-, (C_1-C_6)alkylHN-, (C_1-C_6)alkylamino, [(C_1-C_6)alkyl]$_2$-amino, (C_1-C_6)alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, (C_1-C_6)alkyl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-((C_1-C_6)alkyl)-N-, phenyl-(C=O)-NH-, phenyl-(C=O)-[((C_1-C_6)alkyl)-N]-, (C_1-C_6)alkyl-(C=O)-, phenyl-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, (C_5-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, H_2N(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, ((C_1-C_6)alkyl)$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-, (C_1-C_6)alkyl-(C=O)-O-, (C_1-C_6)alkyl-(C=O)-NH-(C_1-C_6)alkyl, (C_1-C_6)alkyl-NH-(C=O)-(C_1-C_6)alkyl, and (C_1-C_6)alkyl-(C=O)-(C_1-C_6)alkyl, each of which may be optionally substituted by at least one moiety independently selected from the group consisting of (C_1-C_6)alkyl, (C_1-C_6)alkoxy, halo(C_1-C_6)alkyl, halo, H_2N-, NC-, HO-, $Ph(CH_2)_{1-6}HN$-, (C_1-C_6)alkylHN-, (C_5-C_{10})heteroaryl and (C_5-C_{10})heterocyclyl;

R^6 is selected from the group consisting of (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, phenyl, (C_5-C_{10})heteroaryl, (C_5-C_{10})heterocyclic, (C_3-C_{10})cycloalkyl, (C_1-C_6)alkyl-(SO_2)-, (C_1-C_6)alkyl-(SO_2)-(C_1-C_6)alkyl, phenyl-(SO_2), H_2N-(SO_2)-, (C_1-C_6)alkyl-NH-(SO_2)-, (C_1-C_6)alkyl-(SO_2)-NH-(C_1-C_6)alkyl, (C_1-C_6)alkyl-NH-(SO_2)-(C_1-C_6)alkyl, ((C_1-C_6)alkyl)$_2$N-(SO_2)-, phenyl-NH-(SO_2)-, (phenyl)$_2$N-(SO_2)-, (C_1-C_6)alkyl-(C=O)-, (C_1-C_6)alkyl-(C=O)-(C_1-C_6)alkyl, phenyl-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, (C_5-C_{10})heterocyclic-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-(C_3-C_{10})cycloalkyl, (C_1-C_6)alkyl-O-(C=O)-, (C_5-C_{10})heterocyclic-O-(C=O)-, (C_3-C_{10})cycloalkyl-O-(C=O)-, H_2N-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-(C_1-C_6)alkyl, (C_1-C_6)alkyl-(C=O)-NH-(C_1-C_6)alkyl, phenyl-NH-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, (C_5-C_{10})heterocyclic-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-(C_3-C_{10})cycloalkyl, (C_3-C_{10})cycloalkyl-(C=O)-NH-(C_3-C_{10})cycloalkyl, ((C_1-C_6)alkyl)$_2$N-(C=O)-, (phenyl)$_2$N-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heteroaryl-[((C_1-C_6)alkyl)-N]-(C=O)-, (C_5-C_{10})heterocyclic-[((C_1-C_6)alkyl)-N]-(C=O)-, and (C_3-C_{10})cycloalkyl-[((C_1-C_6)alkyl)-N]-(C=O)-, each of which may be optionally substituted by at least one moiety independently selected from the group consisting of halo, (C_1-C_6)alkyl,

PAGE 10/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54

(C_2-C_6)alkenyl, (C_2-C_6)alkynyl, perhalo(C_1-C_6)alkyl, (C_3-C_{10})cycloalkyl, phenyl, benzyl, (C_5-C_{10})heterocyclic, (C_5-C_{10})heteroaryl, (C_1-C_6)alkyl-SO_2-, formyl, NC-, (C_1-C_6)alkyl-(C=O)-, (C_3-C_{10})cycloalkyl-(C=O)-, phenyl-(C=O)-, (C_5-C_{10})heterocyclic-(C=O)-, (C_5-C_{10})heteroaryl-(C=O)-, HO-(C=O)-, (C_1-C_6)alkyl-O-(C=O)-, (C_3-C_{10})cycloalkyl-O-(C=O)-, (C_5-C_{10})heterocyclic-O-(C=O)-, (C_1-C_6)alkyl-NH-(C=O)-, (C_3-C_{10})cycloalkyl-NH-(C=O)-, phenyl-NH-(C=O)-, (C_5-C_{10})heterocyclic-NH-(C=O)-, (C_5-C_{10})heteroaryl-NH-(C=O)-, ((C_1-C_6)alkyl)$_2$-N-(C=O)-, phenyl-[((C_1-C_6)alkyl)-N]-(C=O)-, hydroxy, (C_1-C_6)alkoxy, perhalo(C_1-C_6)alkoxy, (C_3-C_{10})cycloalkyl-O-, phenoxy, (C_5-C_{10})heterocyclic-O-, (C_5-C_{10})heteroaryl-O-, (C_1-C_6)alkyl-(C=O)-O-, (C_3-C_{10})cycloalkyl-(C=O)-O-, phenyl-(C=O)-O-, (C_5-C_{10})heterocyclic-(C=O)-O-, (C_5-C_{10})heteroaryl-(C=O)-O-, O_2N-, amino, (C_1-C_6)alkylamino, ((C_1-C_6)alkyl)$_2$-amino, formamidyl, (C_1-C_6)alkyl-(C=O)-NH-, (C_3-C_{10})cycloalkyl-(C=O)-NH-, phenyl-(C=O)-NH-, (C_5-C_{10})heterocyclic-(C=O)-NH-, (C_5-C_{10})heteroaryl-(C=O)-NH-, (C_1-C_6)alkyl-(C=O)-[((C_1-C_6)alkyl)-N]-, phenyl-(C=O)-[(C_1-C_6)alkyl-N]-, (C_1-C_6)alkyl-SO_2NH-, (C_3-C_{10})cycloalkyl-SO_2NH-, phenyl-SO_2NH-, (C_5-C_{10})heterocyclic-SO_2NH- and (C_5-C_{10})heteroaryl-SO_2NH-;

wherein the phenyl or heteroaryl moiety of a R^6 substituent is optionally further substituted with at least one radical independently selected from the group consisting of (C_1-C_6)alkoxy, perfluoro(C_1-C_6)alkyl and perfluoro(C_1-C_6)alkoxy.

15. (new) A compound according to claim 14 wherein R^1 can optionally be independently substituted with zero to two moieties independently selected from the group consisting of halo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkoxy, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, (C_5-C_{10})ar(C_1-C_6)alkoxy, (C_5-C_{10})heteroar(C_1-C_6)alkoxy, amino, amino(C_1-C_6)alkyl, (C_1-C_6)alkylamino(C_1-C_6)alkyl, di(C_1-C_6)alkylamino(C_1-C_6)alkyl, and (C_5-C_{10})heterocyclyl(C_1-C_6)alkyl.

PAGE 11/14 * RCVD AT 6/15/2006 6:14:56 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/30 * DNIS:2738300 * CSID:7346222928 * DURATION (mm-ss):03-54